Roivant Sciences Ltd. (ROIV) Bernstein 42nd Annual Strategic Decisions Conference May 29, 2026 8:00 AM EDT
Company Participants
Matthew Gline – CEO & Director
Conference Call Participants
William Pickering – Bernstein Institutional Services LLC, Research Division
Presentation
William Pickering
Bernstein Institutional Services LLC, Research Division
All right. Welcome, and good morning. Thank you all for joining us. My name is Will Pickering. I cover U.S. biotech at Bernstein. I have the privilege of sharing the stage with Matt Gline, CEO of Roivant. The company has had a remarkable run over the past year, certainly with brepo as the standout, but far from the only value driver. We’ll dig into that and the other assets over the next 50 minutes conference, I would also like to spend some time on bigger picture questions, the Roivant business model and Matt, your view as an asset hunter about the overall health of the biotech ecosystem today.
For those in the audience, please submit your questions through the Pigeonhole app so we can make this as relevant for you as possible.
Question-and-Answer Session
William Pickering
Bernstein Institutional Services LLC, Research Division
So with that as a preamble, Matt, how would you describe the evolution of Roivant over the past a few years into the company than it is today?
Matthew Gline
CEO & Director
Yes, thanks, and thanks for having me. It’s nice to be here. I appreciate the invitation. Thanks for all the work you guys have done on us. It’s been a fun early run here. So look, it’s always funny when I’m at a more generous event or just like ask to talk about Roivant because I feel like there’s so much complexity in our history in that we got our start as sort of a — whatever these words are all overused, sort of a Maverick outsider biotech company doing
You must be logged in to post a comment Login